Auxilium Biotechnologies, a leader in regenerative medicine, announced the enrolment of the first patient in its clinical trial evaluating the safety and efficacy of NeuroSpan Bridge, an innovative investigational device designed to improve nerve...
Auxilium Biotechnologies, a leader in regenerative medicine, announced the enrolment of the first patient in its clinical trial evaluating the safety and efficacy of...
Route 92 Medical announced its HiPoint Reperfusion System, including the .088in HiPoint 88 aspiration catheter, has shown positive outcomes in the SUMMIT MAX trial...
Natus Medical launched BrainWatch, a point-of-care EEG solution driven by AI. Middleton, Wisconsin-based Natus said its solution brings the reliability and trust expected from...
Inner Cosmos recently reported interim 36-month outcomes from a study of its psychiatric brain-computer interface technology. The company evaluated the safety and feasibility of...
Inner Cosmos recently reported interim 36-month outcomes from a study of its psychiatric brain-computer interface technology. The company evaluated the safety and feasibility of...
Apreo Health announced its emergence from stealth and an upcoming presentation of first-in-human clinical data for its emphysema treatment.
Menlo Park, California-based Apreo develops the...
LumiThera has released new topline data for its Valeda Light Delivery System treatment for slowing the progression of dry age-related macular degeneration (AMD).
LumiThera’s Valeda...
Auxilium Biotechnologies, a leader in regenerative medicine, announced the enrolment of the first patient in its clinical trial evaluating the safety and efficacy of...
Route 92 Medical announced its HiPoint Reperfusion System, including the .088in HiPoint 88 aspiration catheter, has shown positive outcomes in the SUMMIT MAX trial...
Natus Medical launched BrainWatch, a point-of-care EEG solution driven by AI. Middleton, Wisconsin-based Natus said its solution brings the reliability and trust expected from...
Inner Cosmos recently reported interim 36-month outcomes from a study of its psychiatric brain-computer interface technology. The company evaluated the safety and feasibility of...